Michael Frederick Press, MD, PhD

Professor of Pathology

Harold E. Lee Chair in Breast Cancer Research

Director of Breast Cancer Analysis Lab

Image of Michael Frederick Press, MD, PhD
Is this your profile? Click to edit

Overview

Michael F. Press, M.D., Ph.D. is a professor in the Department of Pathology and co-leader of the Women’s Cancers Program. He received his M.D., Ph.D. and residency training at the University of Chicago. He was a member of the University of Chicago faculty for seven years before joining the faculty of the University of Southern California in 1988. Dr. Press is currently the director for the Breast Cancer International Research Group Central Laboratory, the coordinator of the Breast Cancer Program at USC Norris Cancer Center and holds the Harold E. Lee Chair in Cancer Research in the USC Norris Cancer Center. His research interests are molecular genetic alterations in breast and gynecologic cancers.

Research Funding

  • HER-2 NEU PROTO-ONCOGENE IN OVARIAN &ENDOMETRIAL CANCER
    NIH · R01CA050589 · Feb 1, 1991 – Jan 31, 1995 · Role: Principal Investigator
  • PATHOBIOLOGY OF BREAST CANCER AND HORMONE RECEPTORS
    NIH · R01CA048780 · Apr 1, 1988 – Jan 31, 2006 · Role: Principal Investigator

Publications

  • Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer. Cancers (Basel). 2022 Jun 04; 14(11).. View in PubMed
  • Correction to: Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer. Ann Surg Oncol. 2022 May; 29(5):3064.. View in PubMed
  • A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy Alone. Appl Immunohistochem Mol Morphol. 2022 04 01; 30(4):237-245.. View in PubMed
  • Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer. Ann Surg Oncol. 2022 May; 29(5):2882-2894.. View in PubMed
  • A careful reassessment of anthracycline use in curable breast cancer. NPJ Breast Cancer. 2021 Oct 08; 7(1):134.. View in PubMed
  • Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry. J Natl Cancer Inst. 2021 09 04; 113(9):1168-1176.. View in PubMed
  • Cross-ancestry GWAS meta-analysis identifies six breast cancer loci in African and European ancestry women. Nat Commun. 2021 07 07; 12(1):4198.. View in PubMed
  • Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy. PLoS One. 2021; 16(5):e0251163.. View in PubMed
  • Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. Nat Cancer. 2021 04; 2(4):400-413.. View in PubMed
  • Discovery and fine-mapping of height loci via high-density imputation of GWASs in individuals of African ancestry. Am J Hum Genet. 2021 04 01; 108(4):564-582.. View in PubMed